Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
10121 | cabiralizumab |
Synonyms ![]() |
BMS-986227 | FPA-008 | FPA008 |
Comments |
Cabiralizumab is an investigational humanized monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is being investigated for its potential anti-cancer activity. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US20110274683 [1] |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 587 |
Other databases | |
GtoPdb PubChem SID | 315661192 |
Search PubMed clinical trials | cabiralizumab |
Search PubMed titles | cabiralizumab |
Search PubMed titles/abstracts | cabiralizumab |